##  [Novartis pivotal data show children and adolescents with relapsing MS had an 82% lower relapse rate with fingolimod vs. interferon beta-1a](/us-en/news/media-releases/novartis-pivotal-data-show-children-and-adolescents-relapsing-ms-had-82-lower-relapse-rate-fingolimod-vs-interferon-beta-1a-0 "Novartis pivotal data show children and adolescents with relapsing MS had an 82% lower relapse rate with fingolimod vs. interferon beta-1a") 

  Oct 28, 2017